Veradermics, Incorporated (MANE)
Veradermics will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Company Description
Veradermics is a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions.
Our initial focus is developing better treatments for pattern hair loss, a condition affecting approximately 50 million men and 30 million women in the United States.
Veradermics, Incorporated
| Country | United States |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 19 |
| CEO | Reid Waldman, M.D. |
Contact Details
Address: 470 James St. New Haven, CT 06513 United States | |
| Phone | (228) 372-3376 |
| Website | veradermics.com |
Stock Details
| Ticker Symbol | MANE |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1827635 |
| Employer ID | 84-3304423 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Reid Waldman, M.D. | Chief Executive Officer and Director |
| Tim Durso, M.D. | President |
| Dominic Carrano, CPA | Chief Financial Officer |
| Mark Neumann | Chief Commercial and Strategy Officer |
| Michael V. Greco, J.D. | General Counsel |
| John W. Childs | Director |
| Vlad Coric, M.D. | Director |
| Patrick Enright | Director |
| David Friedman, M.D. | Director |
| Jane Grant-Kels, M.D. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 9, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Oct 28, 2025 | D | Notice of Exempt Offering of Securities |
| Oct 27, 2025 | DRS | [Cover] Draft Registration Statement |
| Dec 10, 2024 | D | Notice of Exempt Offering of Securities |
| May 1, 2023 | D | Notice of Exempt Offering of Securities |
| Oct 7, 2021 | D/A | Filing |
| Oct 6, 2021 | D | Notice of Exempt Offering of Securities |
| Oct 9, 2020 | D | Notice of Exempt Offering of Securities |